TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have low or intermediate risk adenocarcinoma of the prostate as defined by:~  * Low-risk disease - Histopathology score (Gleason sum): =\<6, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA: \<10~ * Intermediate-risk disease as either:~    * Histopathology score (Gleason sum) =\< 6, T-stage (per current American Joint Committee on Cancer \[AJCC\] staging criteria): T1c-T2a, and prostate-specific antigen (PSA) \> 10 but =\< 20; or~   * Histopathology score (Gleason sum) 7 with =\< 50% of any cores positive, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA \< 10~* Charlson index of comorbidity score =\< 4~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients with history of inflammatory bowel disease, or who require steroid or cytotoxic therapy for collagen vascular disease~* Patients with a history of cancer other than skin cancer within 5 years of the initiation of protocol treatment~* Patients with a history of pelvic irradiation for any reason~* Life expectancy \< 10 years - Prior treatment with an anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist, or a combination of the two~* Prior radiation therapy, brachytherapy, or cryotherapy~* Prior surgical procedure involving peri-rectal and peri-prostatic area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (standard stereotactic body radiation therapy (SBRT) (Type: ACTIVE_COMPARATOR): Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
- Arm II (four fraction split-course SBRT) (Type: EXPERIMENTAL): Patients undergo 2 fractions of SBRT in weeks 1 and 4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of a Mobile Asthma Adherence Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 11-19~* Asthma diagnosis~* Currently on a daily controller HFA (hydrofluoroalkane) medication for Asthma~* English-speaking~* Has a smartphone or access to a smartphone or tablet~Exclusion Criteria:~* Pregnant~* Foster Care~* Emancipated minor

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Standard Care with Medication Monitoring (Type: SHAM_COMPARATOR): Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor
- Medication Monitoring and Mobile App (Type: EXPERIMENTAL): Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ECMO: Optimization of Its Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* requiring ECMO. For the control,Patients without ECMO admited to ICU.~Exclusion Criteria:~* Age\<18~* Known prisoner of the state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VA ECMO (Type: None): Patients who are placed on VA ECMO.
- VV ECMO (Type: None): Patients who are placed on VV ECMO.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CPAP vs AutoCPAP for Treatment of Obstructive Sleep Apnea (OSA) in the Postoperative Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Known OSA patients well-controlled by CPAP (not hypoxemic i.e. Oxygen Saturation (SaO2) ≥ 89% and post-treatment Apnea Hypopnea (AHI) \<10) and compliant ( \> 3 hours per night) presenting for elective inpatient surgery to MetroHealth Medical Center~2. Elective extremity or lower abdominal surgery~3. Age \>18 years~Exclusion Criteria:~1. Surgery that may cause hypoxemia from causes other than the effect on upper airway patency e.g. any thoracic surgery, upper abdominal surgery, head and neck surgery.~2. Surgery on the upper-airway.~3. Any condition that may interfere with application of CPAP mask e.g. trauma, surgery on the face, vomiting, naso-gastric intubation etc.~4. OSA treated with a device other than CPAP e.g. Bilevel positive pressure or V-Positive Airway Pressure~5. OSA needing very high levels of CPAP i.e. \> 16 cms to achieve adequate control~6. OSA or other underlying cardiopulmonary conditions that require supplemental oxygen~7. Patients with decompensated congestive heart failure or advanced Chronic Obstructive Pulmonary Disease (COPD) (FEV1\<35% of predicted)~8. Patients with neuromuscular impairment~9. Patients with central sleep apnea~10. Pregnant patients~11. Decisional impaired subjects who are not able to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autoadjusting CPAP (VPAP auto) (Type: EXPERIMENTAL): The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
- CPAP arm (usual care) (Type: ACTIVE_COMPARATOR): The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18 years old~2. Subject is able and willing to comply with the follow-up schedule and protocol~3. Chronic, intractable pain in the foot and/or lower leg for at least 6 months~4. Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain~5. Minimum baseline pain rating of 60 mm on the Visual Analog Scale in the primary region of pain~6. Subject is able to provide written informed consent~Exclusion Criteria:~1. Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control~2. Escalating or changing pain condition within the past month as evidenced by investigator examination~3. Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days~4. Subject has had radiofrequency treatment of an intended target Dorsal Root Ganglion within the past 3 months~5. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump~6. Subject is unable to operate the device~7. Subjects with indwelling devices that may pose an increased risk of infection~8. Subjects currently has an active infection~9. Subject has participated in another clinical investigation within 30 days~10. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation~11. Subject has been diagnosed with cancer in the past 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated Subjects (Type: None): All subjects recruited and treated with the Axium neurostimulator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who have an ETG implant in place~* Women who subjectively experience the side effect of an undesirable bleeding profile such as bleeding irregularity or heavy flow after ETG implant was placed and who desire intervention for this side effect by either treatment of bleeding or removal of the implant~* Age 14 years an older, inclusive~Exclusion Criteria:~* Irregular or heavy bleeding from an etiology other than ETG use (e.g. fibroids, cervical polyp, or other organic cause of bleeding)~* Has attempted prescription treatment for menstrual side effects while using ETG implant~* Has one or more of the conditions considered Category 3 (risks outweigh benefits) or Category 4 (unacceptable health risk) for estrogen-containing oral contraceptives by the Center for Disease Control Medical Eligibility Criteria for Contraceptive Use:~  * Current or history of heart or vascular diseases, including deep venous thrombosis, pulmonary embolism, known thrombogenic mutations, peripartum cardiomyopathy, and complicated valvular heart disease~ * Hypertension, even if adequately controlled~ * Diabetes with vascular involvement~ * Headaches with focal aura, or migraines in women age 35 and older even without focal aura~ * Major surgery with prolonged immobilization~ * Breast cancer (current or past)~ * Severe (decompensated) cirrhosis~ * Acute or flare viral hepatitis~ * Breastfeeding less than 1 month postpartum~ * Post-partum less than 3 weeks~ * 35 years of age and older and smoking~ * Multiple risk factors for arterial cardiovascular disease~ * Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies~ * Current symptomatic gallbladder disease or history of cholestasis related to past combined oral contraceptive use~ * On certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine, lamotrigine)~ * On Ritonavir-boosted protease inhibitors for antiretroviral therapy~* Issues or concerns, in the judgment of the investigator, that may compromise the safety of the subject, impact the subject's adherence to the protocol requirements, or confound the reliability of the data acquired in this study

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EE 30mcg/LNG 150mcg (Type: ACTIVE_COMPARATOR): combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comminuted Intra-Articular Distal Tibia Fracture Fixation Using Computer Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Adults 18 to 75 years old.~2. Diagnosis of a closed or open, isolated intra-articular comminuted distal tibia fracture (OTA 43-C), with plans for delayed definitive surgery. May have concomitant fracture or injury of fibula.~3. Standard of care imaging available for pre-operative assessment and modeling~4. English speaking.~5. Available for follow-up for 12 months.~6. Patient signs informed consent.~Exclusion Criteria~1. History of musculoskeletal disease of the foot and/or ankle (i.e. arthritis).~2. Non-ambulatory prior to injury.~3. Bilateral lower extremity fractures.~4. Fracture of ipsilateral talus or calcaneus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
- Intervention (Type: EXPERIMENTAL): A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subjective Perception of Motor Control During Psychogenic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Medical exam médical done before study participation~* Between 18 and 65 years~* Right-handed persons~* Conversion disorder based on DSM IV-R criterias~* Symptom affecting motor system, like abnormal movements (shivers, dystonia, parkinsonism, or problem when walking)~Exclusion Criteria:~* Subjects included in a clinical and/or therapeutic exeprimentation in progress~* People with MRI contraindications : prosthesis or metal implants, metallic teeth (dental) brace, pacemaker, IUD, possibility of pregnancy, claustrophobia~* Traitement médicamenteux psychotrope ou susceptible d'interférer avec le débit sanguin cérébral ou l'activité neuronale~* History of brain or disseminated and extendible lesions of white matter, of an other degenerative morbidity, a confusion or an insanity as well as serious deficits preventing language understanding.~* Alcohol ingestion~* Pregnant, parturient or breastfeeding women~* All other categories of protected persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psychogenic disorders (Type: EXPERIMENTAL): Psychogenic movement disorders and seizures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neural Correlates of Intern Speech

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 65 years~* Right-handed~* French as mother tongue~* Visual acuity that allow to read stimulis (contact lens authorized)~* Healthy subject~Exclusion Criteria:~* Respiratory or cardio-vascular pathology~* Claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with relapsed and/or refractory myeloma who have received between 1-4 prior lines of therapy~* Must have adequate liver and renal function~* Zubrod Performance Status (ZPS) of 2 or better~* Must have measurable disease~Exclusion Criteria:~* Peripheral neuropathy of grade II or higher~* Thrombocytopenia (platelets less than 50,000/uL)~* Neutropenia (ANC\<1000/uL)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.4 X ULN~* Total bilirubin \>1.5 X upper limit of normal (ULN)~* Creatinine clearance of less than 45 milliliters per minute (mL/min)~* Patients with HIV~* Patients with active hepatitis~* Pregnant or lactating women~* Individuals of child-bearing potential not using adequate contraception~* Individuals unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine (Type: EXPERIMENTAL): Bendamustine is combined with standard chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Whole-body Vibration Physiotherapy in Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Kidney transplantation in the last 12 months~* Stable kidney function (eGFR\>20 ml/min)~* No episode of acute rejection during the last 2 months~* Written informed consent~Exclusion Criteria~* Inability to posture or to perform whole-body vibration therapy or MRS after transplantation~* Treatment with anabolic medication, fluorine, bisphosphonates, or hormone replacement therapy (estrogens, selective modulators of the estrogenic receptors) within the previous 3 months~* Treatment with high-dose steroid therapy due to acute rejection episode during the last 2 months before study inclusion~* Implanted devices (pacemakers, defibrillators, stents, etc.)~* Pregnancy~* Previous ophthalmic cataract surgery~* Previous history of epilepsy~* Previous recent spine of leg fracture (last 3 months)~* Other individuals especially in need of protection (according to the Swiss Academy of Medical Sciences)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Physiotherapeutical intervention (Type: ACTIVE_COMPARATOR): 3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
- Sham physiotherapeutical intervention (Type: SHAM_COMPARATOR): 3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Interface With/Without Oral Appliance of Sleep Apnea Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* normal nasal breathing~* dentition allowing for use of an oral appliance~* absence of mandibular joint pathology~* Patients requiring the use of a facial mask during CAPP titration due to presence of mouth leaks with a nasal/prong interface~* Patients using CPAP less than 3 hours/day as prescribed following CPAP titration~Exclusion Criteria:~* Clinical instability~* smoking cessation~* current weight loss strategy~* Marked anatomic abnormalities of upper airway (i.e. macroglossia, tonsils hypertrophy)~* severe cardio-metabolic co-morbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oro-nasal mask (Type: ACTIVE_COMPARATOR): Oro-nasal mask during 1 month of auto CPAP
- Nasal mask and oral appliance (Type: EXPERIMENTAL): Nasal mask and oral appliance during 1 month of auto CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Albumin to Reduce Inflammation Following Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients over sixteen years of age undergoing surgery that requires cardiopulmonary bypass who provide informed written consent~Exclusion Criteria:~* Lack of informed consent~* Pregnancy~* Cyanotic congenital heart disease (due to high haemoglobin levels and increased haemolysis)~* Patients undergoing other extracorporeal interventions (ventricular assist devices, extracorporeal membrane oxygenators, pre-admission dialysis)~* Patients with congenital haemoglobinopathies (e.g. thalassaemia, cryoglobinuria, etc)~* Patients with disorders of iron metabolism (e.g. haemochromatosis)~* Religious objections to transfusion of a plasma-derived product~* Patients with known blood borne infection~* Patients with known hypersensitivity to gelofusine or human albumin solution~* Patients with an additive EUROSCORE of 10 or more

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Albumin (Type: EXPERIMENTAL): Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
- 2 Gelofusin (Type: PLACEBO_COMPARATOR): Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues